| Ytd | 29.80% | |
| 1y | 85.16% |
| Open | 15.21 | Prev Close | 13.85 | Low | 13.76 | High | 16.52 | Mkt Cap | 18.59M |
| Vol | 219.47K | Avg Vol | 53.60K | EPS | -142.72 | P/E | N/A | Forward P/E | -0.40 |
| Beta | -0.25 | Short Ratio | 0.29 | Inst. Own | 8.81% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-08 | 50-d Avg | 0.51 | 200-d Avg | 0.75 | 1yr Est | 4.13 |
SNSE News
AUSTIN, Texas--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it
Wall Street analysts changed outlook on top names like MKTX, PRCT, VOD, and JILL. See ratings page a
Wall Street analysts change outlook for top stocks. See upgrades, downgrades, and initiations on ana
Top Wall Street analysts change outlook on top names. See analyst ratings page for changes, includin
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Com
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the first quarter e
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial result
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that Company ma
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial result
Sensei Biotherapeutics (NASDAQ: SNSE - Get Free Report) is expected to be announcing its Q4 2025 res
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider. com News Commentary
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE - Get Free Report) was the recipient of a large increase
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective
SNSE up on acquisition of Faeth Therapeutics, $200M private placement, and addition of PIKTOR to pip
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acq
Cynata Therapeutics (OTCMKTS:CYYNF - Get Free Report) and Sensei Biotherapeutics (NASDAQ: SNSE - Get
PARIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics SAS (Egle), a clinical-stage biotechnolog
Sensei Biotherapeutics surged in after-hours trading Thursday, with strong recent gains and ongoing
BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical st
BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-st